Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: A 12-month randomized trial

Mark B. Sherwood, Earl Randy Craven, Connie Chou, Harvey B. DuBiner, Amy L. Batoosingh, Rhett M. Schiffman, Scott M. Whitcup

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of a fixed combination of 0.2% brimonidine tartrate and 0.5% timolol maleate (fixed brimonidine-timolol) compared with the component medications. Methods: In 2 identical, 12-month, randomized, double-masked multicenter trials, patients with ocular hypertension or glaucoma were treated with fixed brimonidine-timolol twice daily (n = 385), 0.2% brimonidine tartrate 3 times daily (n = 382), or 0.5% timolol maleate twice daily (n = 392). Main Outcomes Measures: Mean change from baseline IOP and incidence of adverse events. Results: The mean decrease from baseline IOP during 12-month follow-up was 4.4 to 7.6 mm Hg with fixed brimonidine-timolol, 2.7 to 5.5 mm Hg with brimonidine, and 3.9 to 6.2 mm Hg with timolol. Mean IOP reductions were significantly greater with fixed brimonidine-timolol compared with timolol at all measurements (P≤.002) and brimonidine at 8 AM, 10 AM, and 3 PM (P

Original languageEnglish (US)
Pages (from-to)1230-1238
Number of pages9
JournalArchives of Ophthalmology
Volume124
Issue number9
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Timolol
Ocular Hypertension
compound A 12
Intraocular Pressure
Glaucoma
Therapeutics
Multicenter Studies
Outcome Assessment (Health Care)
Safety
Timolol Maleate Drug Combination Brimonidine Tartrate
Brimonidine Tartrate
Incidence

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension : A 12-month randomized trial. / Sherwood, Mark B.; Craven, Earl Randy; Chou, Connie; DuBiner, Harvey B.; Batoosingh, Amy L.; Schiffman, Rhett M.; Whitcup, Scott M.

In: Archives of Ophthalmology, Vol. 124, No. 9, 2006, p. 1230-1238.

Research output: Contribution to journalArticle

Sherwood, Mark B. ; Craven, Earl Randy ; Chou, Connie ; DuBiner, Harvey B. ; Batoosingh, Amy L. ; Schiffman, Rhett M. ; Whitcup, Scott M. / Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension : A 12-month randomized trial. In: Archives of Ophthalmology. 2006 ; Vol. 124, No. 9. pp. 1230-1238.
@article{925123ce03b2486d9a4760d0df43ae8a,
title = "Twice-daily 0.2{\%} brimonidine-0.5{\%} timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: A 12-month randomized trial",
abstract = "Objective: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of a fixed combination of 0.2{\%} brimonidine tartrate and 0.5{\%} timolol maleate (fixed brimonidine-timolol) compared with the component medications. Methods: In 2 identical, 12-month, randomized, double-masked multicenter trials, patients with ocular hypertension or glaucoma were treated with fixed brimonidine-timolol twice daily (n = 385), 0.2{\%} brimonidine tartrate 3 times daily (n = 382), or 0.5{\%} timolol maleate twice daily (n = 392). Main Outcomes Measures: Mean change from baseline IOP and incidence of adverse events. Results: The mean decrease from baseline IOP during 12-month follow-up was 4.4 to 7.6 mm Hg with fixed brimonidine-timolol, 2.7 to 5.5 mm Hg with brimonidine, and 3.9 to 6.2 mm Hg with timolol. Mean IOP reductions were significantly greater with fixed brimonidine-timolol compared with timolol at all measurements (P≤.002) and brimonidine at 8 AM, 10 AM, and 3 PM (P",
author = "Sherwood, {Mark B.} and Craven, {Earl Randy} and Connie Chou and DuBiner, {Harvey B.} and Batoosingh, {Amy L.} and Schiffman, {Rhett M.} and Whitcup, {Scott M.}",
year = "2006",
doi = "10.1001/archopht.124.9.1230",
language = "English (US)",
volume = "124",
pages = "1230--1238",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension

T2 - A 12-month randomized trial

AU - Sherwood, Mark B.

AU - Craven, Earl Randy

AU - Chou, Connie

AU - DuBiner, Harvey B.

AU - Batoosingh, Amy L.

AU - Schiffman, Rhett M.

AU - Whitcup, Scott M.

PY - 2006

Y1 - 2006

N2 - Objective: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of a fixed combination of 0.2% brimonidine tartrate and 0.5% timolol maleate (fixed brimonidine-timolol) compared with the component medications. Methods: In 2 identical, 12-month, randomized, double-masked multicenter trials, patients with ocular hypertension or glaucoma were treated with fixed brimonidine-timolol twice daily (n = 385), 0.2% brimonidine tartrate 3 times daily (n = 382), or 0.5% timolol maleate twice daily (n = 392). Main Outcomes Measures: Mean change from baseline IOP and incidence of adverse events. Results: The mean decrease from baseline IOP during 12-month follow-up was 4.4 to 7.6 mm Hg with fixed brimonidine-timolol, 2.7 to 5.5 mm Hg with brimonidine, and 3.9 to 6.2 mm Hg with timolol. Mean IOP reductions were significantly greater with fixed brimonidine-timolol compared with timolol at all measurements (P≤.002) and brimonidine at 8 AM, 10 AM, and 3 PM (P

AB - Objective: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of a fixed combination of 0.2% brimonidine tartrate and 0.5% timolol maleate (fixed brimonidine-timolol) compared with the component medications. Methods: In 2 identical, 12-month, randomized, double-masked multicenter trials, patients with ocular hypertension or glaucoma were treated with fixed brimonidine-timolol twice daily (n = 385), 0.2% brimonidine tartrate 3 times daily (n = 382), or 0.5% timolol maleate twice daily (n = 392). Main Outcomes Measures: Mean change from baseline IOP and incidence of adverse events. Results: The mean decrease from baseline IOP during 12-month follow-up was 4.4 to 7.6 mm Hg with fixed brimonidine-timolol, 2.7 to 5.5 mm Hg with brimonidine, and 3.9 to 6.2 mm Hg with timolol. Mean IOP reductions were significantly greater with fixed brimonidine-timolol compared with timolol at all measurements (P≤.002) and brimonidine at 8 AM, 10 AM, and 3 PM (P

UR - http://www.scopus.com/inward/record.url?scp=33748596339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748596339&partnerID=8YFLogxK

U2 - 10.1001/archopht.124.9.1230

DO - 10.1001/archopht.124.9.1230

M3 - Article

C2 - 16966616

AN - SCOPUS:33748596339

VL - 124

SP - 1230

EP - 1238

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 9

ER -